key: cord-0281940-wvrypl98
authors: To, Albert; Wong, Teri Ann S.; Lieberman, Michael M.; Thompson, Karen; Pessaint, Laurent; Greenhouse, Jack; Daham, Nisrine; Cook, Anthony; Narvaez, Brandon; Flinchbaugh, Zack; Ry, Alex Van; Yalley-Ogunro, Jake; Elyard, Hanne Andersen; Lai, Chih-Yun; Donini, Oreola; Lehrer, Axel T.
title: Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1
date: 2021-09-25
journal: bioRxiv
DOI: 10.1101/2021.09.24.461759
sha: 055a2b6f8874c589a39f673cedfd6a25c50cc9de
doc_id: 281940
cord_uid: wvrypl98

FDA-approved and Emergency Use Authorized (EUA) vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease, however, information on their long-term efficacy and protective breadth against SARS-CoV-2 Variants of Concern (VOCs) is currently scarce. Here we describe the durability and broad-spectrum VOC immunity of a prefusion-stabilized spike (S) protein adjuvanted with liquid or lyophilized CoVaccine HT™ in cynomolgus macaques. This recombinant subunit vaccine is highly immunogenic and induces robust spike-specific and broadly neutralizing antibody responses effective against circulating VOCs (B.1.351 [Beta], P.1 [Gamma], B.1.617 [Delta]) for at least 3 months after the final boost. Protective efficacy and post-exposure immunity were evaluated using a heterologous P.1 challenge nearly 3 months after the last immunization. Our results indicate that while immunization with both high and low S doses shorten and reduce viral loads in the upper and lower respiratory tract, a higher antigen dose is required to provide durable protection against disease as vaccine immunity wanes. Histologically, P.1 infection causes similar COVID-19-like lung pathology as seen with early pandemic isolates. Post-challenge IgG concentrations were restored to peak immunity levels and vaccine-matched and cross-variant neutralizing antibodies were significantly elevated in immunized macaques indicating an efficient anamnestic response. Only low levels of P.1-specific neutralizing antibodies with limited breadth were observed in control (non-vaccinated but challenged) macaques suggesting that natural infection may not prevent reinfection by other VOCs. Overall, these results demonstrate that a properly dosed and adjuvanted recombinant subunit vaccine can provide long-lasting and protective immunity against circulating VOCs. One Sentence Summary A recombinant subunit protein formulated with CoVaccine HT™ adjuvant induces superior immunity than natural infection and reduces viral load while protecting cynomolgus macaques from COVID-19-like disease caused by late SARS-CoV-2 P.1 (Gamma) challenge.

range of 70 to 753 μg/mL. Macaques given a 25 μg dose of S demonstrated a greater IgG 140 response to the antigen compared to those receiving 5 μg. RBD-specific IgG titers followed a 141 similar trend. As expected, animals in group D receiving an unrelated antigen did not develop 142 any detectable S-specific IgG during this phase of the study. S-specific IgG remained detectable 143 12 weeks after the boost (week 15) although IgG concentrations dropped 3.0 to 9.9-fold relative 144 to the prior peak titer. 145

The titer of NtAb against the prototype WA1/2020 strain was determined using a standard 147 PRNT with wild-type virus (Fig. 1C) . NtAb from one animal in Group C was detectable after the 148 prime (week 3). All S-immunized NHPs developed a potent neutralizing response, peaking two 149 weeks after the boost (week 5) and generally remaining stable one week later (week 6). The 150 group receiving 5 μg of the antigen showed the greatest variability. Nearly all immunized NHPs 151 maintained neutralization capacity, with PRNT 50 greater than 1:150 dilution, 12 weeks after the 152 final immunization (week 15). NtAbs from groups receiving 25 μg S either remained stable or 153 decreased up to 3.0-fold, while the group receiving 5 μg S declined ~2.9-9.2-fold. A similar 154 reduction in serum neutralization was also verified using a surrogate rVSV-SARS-CoV-2 S 155 PRNT assay (Fig. S2) . to week 6, suggesting a refinement or "maturation" of the humoral response towards 173 neutralizing epitopes during this interval. 174 pathology, a section slide from each lung lobe and the bronchi was prepared from each 217 macaque and stained with hematoxylin and eosin to survey for histopathological changes 218 indicative of acute lung injury. The histopathological scoring system based on the 219 presence/severity of edema, intraalveolar and interstitial inflammation, perivascular lymphocytic 220 cuffing, and increased bronchiolar-associated lymphoid tissue (BALT) is outlined in Table S1 . A 221 cumulative average score was determined for each macaque based on the evaluation of these 222 five characteristics per section for a total of 30 scores (Fig 4A) . Significant differences in the 223 cumulative average scores for each vaccine formulation vs. controls were determined using a 224 one-way ANOVA followed by a Dunnett's multiple comparison test. Macaques in the control 225

Group D appeared to have developed mild to moderate respiratory disease. The lower 226 cumulative GMT scores of Groups B and C, immunized with 25 μg S, suggests that these 227 animals, except for a single macaque, were completely protected from lung pathology while all 228

Group A (immunized with 5 μg S) macaques appeared to have developed mild disease despite 229 exhibiting lower viral loads. Week 15 WA1/2020 NtAb levels were determined to be inversely 230 correlated, although weakly, with histopathology scores using a Spearman's correlation test (r=-231 0.682, p=0.0178) (Fig. 4B ). Week 15 pre-challenge neutralizing antibody levels were lower in 232 animals with higher histopathology scores, a trend seen with breakthrough infections in fully 233 immunized individuals (64). The moderate disease seen in the control animals is demonstrated (especially those receiving the higher antigen dose), appeared to have milder disease without 237 these pathological changes (Fig. 5B ). Macaques developing mild to moderate disease exhibited 238 absent to moderate, focal and multifocal edema and perivascular cuffing with suggesting that a recall response was triggered by the heterologous infection (Fig. 7A ). levels were also all significantly boosted to levels attaining or surpassing the peak levels 262 generated through initial immunization by 5-fold and upwards of 20-fold respectively (Fig. 7B  263 and S2). Unsurprisingly, the greatest increase from pre-challenge neutralization was against the 264 P.1 challenge isolate. Group A showed slightly higher P.1 NtAbs compared to Group B and C 265 macaques and was the only group to have significantly higher titers across different variants. 266

The lower degree of histopathology seen in Groups B and C may indicate that 25 μg S with 267 either form of CoVaccine HT TM provides greater long-term protection. In Group D control 268 macaques, P.1 challenge generated low levels of NtAbs compared to immunization alone, and it 269 was only cross-reactive with the B.1.351 isolate and not to WA1/2020 nor B.1. 617 isolates. 270 This suggests that primary infection with one isolate of SARS-CoV-2 does not generate broad 271 immunity against other variants in contrast to vaccine derived immunity, which is more broadly 272 cross-reactive with VOCs, even months after peak immunity is observed. 96-well plate. All samples were tested in triplicate. Control RNA was prepared to contain 10 6 to 513 10 7 copies per 3 µL. Eight (8) 10-fold serial dilutions of control RNA were prepared and 514 produced a standard curve with a range of 1 to 10 7 copies/reaction. For amplification, the plate 515 was placed in an Applied Biosystems 7500 Sequence detector and amplified using the following 516 program: 48ºC for 30 minutes, 95ºC for 10 minutes followed by 40 cycles of 95ºC for 15 517 seconds, and 1 minute at 55ºC. Duplicate samples of each dilution were prepared as described 518

above. If the copy number exceeded the upper detection limit, the sample was diluted as 519 curve and multiplying by the reciprocal of 0.2 mL extraction volume. This gave a practical range 521 of 50 to 5 x 10 8 RNA copies per mL for BAL samples and for nasal and oral swabs the viral 522 loads were given per swab. 523

The RT-PCR assay for the sgRNA utilizes primers and a probe specifically designed to amplify 525 and bind to a region of the N gene mRNA from the Coronavirus, which is not packaged into the 526 virion. The signal was compared to a known standard curve of plasmid containing the sequence 527 of part of the messenger RNA and calculated to give copies per ml. The control DNA was 528 prepared to contain 10 7 copies. Seven 10-fold serial dilutions of control RNA were prepared 529 using Buffer AVE and generated a standard curve with a range of 1 to 10 6 copies/reaction. 530

Duplicate samples of each dilution were prepared as described above with the primer pair (SG-531 N-F: CGATCTCTTGTAGATCTGTTCTC and SG-N-R: GGTGAACCAAGACG CAGTAT) and 532 probe (FAM-TAACCAGAATGGAGAACGCAGTGGG -BHQ). If the copy number exceeded the 533 upper detection limit, the sample was diluted as needed. For amplification, the plate was placed 534 in an Applied Biosystems 7500 Sequence detector and amplified using the following program: 535 48°C for 30 minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds, and 1 536 minute at 55°C. The number of copies of RNA per ml was calculated by interpolation from the 537 standard curve and multiplying by the reciprocal of 0.2 ml extraction volume. This gave a 538 practical range of 50 to 5 x 10 7 RNA copies per mL for harvested samples. Wuhan-Hu-1 S-specific IgG kinetics measured using a MIA with purified, human S-specific IgG standards to estimate serum concentration. The presence and severity of edema, intra-alveolar inflammation, perivascular cuffing, increased BALT and interstitial inflammation was determined and assigned scores ranging from 0-3. Significant differences in lung histopathology were calculated using a one-way ANOVA followed by a Dunnett's multiple comparison to Group D with the scores from each section (30 scores per macaque) as replicates. Horizontal bars mark the GMT of each group. (**p≤0.01, ****p≤0.0001) (B) Correlation between histopathology scores and WA1/2020-specific PRNT 50 titers were determine using a Spearman's correlation test. 

Presenting Characteristics, Comorbidities, and Outcomes Among

Patients Hospitalized With COVID-19 in the New York City Area

Presumed Asymptomatic Carrier Transmission of COVID-19

Estimating the generation interval for coronavirus disease (COVID-19) 586 based on symptom onset data

Temporal dynamics in viral shedding and transmissibility of COVID-19

Seroprevalence and humoral immune durability of anti-SARS-CoV-2

China: a longitudinal, population-level, cross-sectional study

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild

Confirmed Reinfection with SARS-CoV-2 Variant

Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare 608 Worker in Italy Confirmed by Whole-Genome Sequencing

A case of SARS-CoV-2 reinfection in Ecuador

Genomic evidence for reinfection with SARS-CoV-2: a case study

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Spike mutation D614G alters SARS-CoV-2 fitness

SARS-CoV-2 B.1.617.2 Delta variant replication and immune 620 evasion

Resurgence of COVID-19 in Manaus, Brazil, despite high preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-Covid-19

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B

COVID-19 mRNA vaccine induced antibody responses against three

SARS-CoV-2 variants

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 663 variants

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 665 vaccine-elicited human sera

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by 667 convalescent and vaccine sera

Sucrose fatty acid sulphate esters as novel vaccine adjuvant

Vaccine 24 Suppl

Covid-19 Breakthrough Infections in Vaccinated Health Care

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Vaccine breakthrough infection and onward transmission of SARS-CoV-2

Evidence for increased breakthrough rates of SARS-CoV-2 variants of 687 concern in BNT162b2-mRNA-vaccinated individuals

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully 689

Emerging infectious diseases

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine

Breakthrough Infections, Associated with Large Public Gatherings -Barnstable County

Cellular events of acute, resolving or progressive COVID-19 in

SARS-CoV-2 infected non-human primates

Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using

Recombinant protein vaccines against SARS-CoV-2. Lancet 708 Infect Dis

SARS-CoV-2 protein subunit vaccination of mice and rhesus 710 macaques elicits potent and durable neutralizing antibody responses

Safety and immunogenicity of SARS-CoV-2 recombinant protein 713 vaccine formulations in healthy adults: interim results of a randomised, placebo-714 controlled, phase 1-2, dose-ranging study

Preservation of Quaternary Structure in Thermostable

Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays

Single-vial filovirus glycoprotein vaccines: Biophysical 719 characteristics and immunogenicity after co-lyophilization with adjuvant

Genomics and epidemiology of a novel SARS-CoV-2 lineage in

Epidemiology of SARS-CoV-2

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in 735 macaques

Durable Humoral and Cellular Immune Responses Following

S Vaccination for COVID-19. medRxiv

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV

with Continued Evolution to Variants of Concern. bioRxiv : the preprint server for biology

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-742 2 variants

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Vaccine Breakthrough Infections with

747 : the preprint server for biology

A simple method of estimating fifty percent end points

Acknowledgements: We would like to thank Takaji Wakita, from the National Institute of 762 Infectious Diseases, Japan, for the P.1 viral challenge strain

USA, for deep sequencing our inhouse 764 viral stock. We also would like to thank Adrian Creanga from the Vaccine Research Center

USA for the Vero TMPRSS2 cell line used in our TCID 50 and PRNT 50 assays

CoV 2 virus stock 767 used in our surrogate PRNT 50 assay. Furthermore, we would like to thank Melissa Hamilton, the 768 study coordinator at Bioqual Inc., USA; Mapp Biopharmaceutical Inc, for the CR3022 mAb used 769 for protein purification; BTG International Limited for the CoVaccine HT TM adjuvant

Ewall from the JABSOM Histocore for preparing lung tissue sections for 771 histopathological analysis

JYO 783 Formal Analysis: AT, MML, KT, ATL 784 Visualization: AT, KT 785 Funding acquisition: OD, ATL 786 Project administration: HA, OD, ATL 787 Supervision: HA, OD, ATL 788 Writing -original draft: AT, KT, ATL 789 Writing -review & editing: AT

Competing Interests: 792 ATL and OD are named inventors on a patent application covering a recombinant subunit 793 vaccine for SARS-CoV-2

OD is a current employee of Soligenix Inc. All other authors declare no